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The objective of this study was to develop a criteria catalogue serving as a guideline for authors to improve quality of reporting
experiments in basic research in homeopathy. A Delphi Process was initiated including three rounds of adjusting and phrasing
plus two consensus conferences. European researchers who published experimental work within the last 5 years were involved.
A checklist for authors provide a catalogue with 23 criteria. The “Introduction” should focus on underlying hypotheses, the
homeopathic principle investigated and state if experiments are exploratory or conﬁrmatory. “Materials and methods” should
comprise information on object of investigation, experimental setup, parameters, intervention and statistical methods. A more
detailed description on the homeopathic substances, for example, manufacture, dilution method, starting point of dilution is
required. A further result of the Delphi process is to raise scientists’ awareness of reporting blinding, allocation, replication,
quality control and system performance controls. The part “Results” should provide the exact number of treated units per setting
which were included in each analysis and state missing samples and drop outs. Results presented in tables and ﬁgures are as
important as appropriate measures of eﬀect size, uncertainty and probability. “Discussion” in a report should depict more than a
general interpretation of results in the context of current evidence but also limitations and an appraisal of aptitude for the chosen
experimental model. Authors of homeopathic basic research publications are encouraged to apply our checklist when preparing
their manuscripts. Feedback is encouraged on applicability, strength and limitations of the list to enable future revisions.
1.Introduction
Homeopathy is a widely used and highly controversial
complementary therapy. The central aspect of the dispute
is the use of highly diluted, “potentized” remedies which,
according to conventional scientiﬁc thinking, make any
biological activity highly unlikely. But also the validity of
the fundamental tenet of homeopathy—the Similia Principle
(like cures like)—is not generally accepted by the scientiﬁc
community. Therefore, any publication of a research study
in homeopathy, particularly if reporting positive results, is
subjected to special scrutiny. Clinical research is of utmost
importance to investigate eﬃcacy and eﬀectiveness. Basic
research is needed to investigate possible mechanisms of
action. However, as clinical research so far has failed to prove
or disprove speciﬁc eﬀects of homeopathy in general and
of high potencies in particular, laboratory research is also
needed to investigate whether homeopathic preparations
have biological activity.
Publishedexperimentscanbeassignedtofourmainareas
of basic research on homeopathy: animal research, plant
bioassays, in vitro models and physicochemical research [1].2 Evidence-Based Complementary and Alternative Medicine
The HomBrex Database lists more than 1100 experiments
published in about 900 publications in diﬀerent ﬁelds of
basicresearch[2].Toappreciateandunderstandthemethods
and ﬁndings of such studies, a high degree of transparency
is required from authors. Reviews have shown that many
experiments diﬀer in design and quality [3]. Over the
years, several eﬀorts have been made to enhance the quality
of basic research in homeopathy. Schulte proposed a set
of standards for ultra high dilution research [4], Linde
et al. worked out checklists for preparing and reviewing
publications [5] and also suggestions on methodological
standards[6]havebeenpublished.Moreoverscoringsystems
for assessing quality were generated: the ﬁrst for the use in
experimental toxicology [7] the second for physicochemical
researchintohomeopathicpotentization[8].Thelatterscore
was modiﬁed and used in a systematic review on in vitro
experiments [3].
It seemed reasonable to try to bring together all aspects
of former evaluation scores and to develop with a team of
experienced researchers a basic score applicable (possibly in
a slightly adjusted format) in all ﬁelds of basic research on
homeopathy. During the discussion process it was decided
to shift the focus from the development of a scoring system
to the development of a reporting checklist for authors, peer
reviewers and editors (and possibly readers and authors of
systematic reviews) similar to publication guidelines in clin-
ical research (CONSORT, REDHOT). This article describes
and discusses the development process of the checklist
(REHBaR—Reporting Experiments in Homeopathic Basic
Research). A second publication will focus on the last step of
the Delphi Process (round V), where the discussed criteria
and their detailed explanations as a result of the whole
process are given, supported and further evidenced from
other publications.
2. Methods
2.1. The Delphi Process: A Consensus Method. From the
existing consensus methods we chose a Delphi approach.
Delphi may be characterized as a method for structuring a
group communication process so that the process is eﬀective
in allowing a group of individuals, as a whole, to deal with a
complex problem. In order to obtain a useful result for their
objective there is a need to structure a group communication
process[9].ThisDelphitechniqueisapplicabletoavarietyof
questionsendingupwithdiﬀerentoutcomes.Inourcase,the
goal was to create an agreed checklist with criteria important
for improving the quality of reports in basic research. A
search for papers in the databases PubMed and CAMbase
with the following keywords was conducted until July 2009:
guideline, reporting, publication, catalogue, basic, clinical,
fundamental, research, author, quality, CONSORT.
2.2. Preparatory Work. Before starting the Delphi process a
preliminary collection of 58 potentially relevant items was
compiled as preparatory work. The collection comprised all
items included in the two scores developed for systematic
reviews in basic research [7, 8]. Additional items were
includedonthebasisofinformaldiscussionwithexpertsand
the corresponding author.
2.3. The Delphi Process (Round I–V). In the Delphi process
there were a total of ﬁve rounds, including two consensus
conferences (see Figure 1). In Delphi I, the list of 58 items
primed in the preparatory phase by the initiators was
sent to all participants. All experts were asked to rate the
importance of each item on a 5-point Likert scale, and
to add further items. Delphi II—the ﬁrst conference—
oﬀered the opportunity to clarify misunderstandings and
misconceptions and discuss the objective of the catalogue
in general. In Delphi III a modiﬁed catalogue was prepared
taking into account the revised objective (see “Results”),
which was again discussed in the conference Delphi IV.
In Delphi V, the reporting document was prepared and
iteratively revised in an internal review process.
2.4. Team of Experts. Members of the panel were S. Baum-
gartner, L. Betti, C. Endler and R. van Wijk as leading
European researchers in homeopathic experiments with
plants, animals, evolutionary biology as well as biochemical
and biophysical research. K. Linde and C. Witt were involved
in Delphi for two reasons: ﬁrst they are well known experts
in the ﬁeld of clinical research concerned with quality
questions, and secondly both are experienced in basic
researchanddevelopedascoreforqualityassessmentinbasic
research [7, 8]. R. L¨ udtke was responsible for the statistical
aspects, H. Albrecht, G. Dobos and F. Musial for general
support in questions of basic research.
3. Results
3.1. Delphi Round I: Rating and Selection of Items. In the ﬁrst
round, all members of the team rated the relevance of the
58 items included in the preliminary list. Out of 58 items,
18 were rated as “absolutely necessary” (mean: 3.5–4) and 31
items as “moderately necessary” (mean: 2.5–3). No item was
rated “moderately unnecessary” or “strongly unnecessary”,
but nine items received neutral rating (mean: 2). Only one
item was added and discussed in the conference.
3.2. Delphi Round II: The First Consensus Conference. In
the ﬁrst conference we came to the conclusion that our
initial intention—creating a new evaluation score—should
be postponed. A criteria catalogue for improving the quality
ofreportingexperimentswasconsideredapriority.Themain
reason for this was that accurate reporting is a precondition
for a valid quality assessment. Furthermore, the importance
of quality scoring, in clinical research, is currently under dis-
cussion. For example, the current version of the Handbook
of the Cochrane Collaboration, a worldwide network for
performing systematic reviews on clinical research, explicitly
discourages the use of quality scores [10]: it is argued that
while this method of scoring is simple, it is not supported
by empirical evidence. The calculation of summary scores
involves assigning “weights” to diﬀerent items in the scale,
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scales have been shown to be unreliable assessments of
validity [11] .T h e r e f o r ei ti sr e g a r d e da sp r e f e r a b l et ou s e
simple approaches for assessing validity that can be fully
reported (i.e., how each trial was rated on each criterion).
3.3. Delphi Round III: Phrasing of the Checklist. As a result,
a checklist for adequate reporting was then compiled and
worded in this round following existing examples in clinical
research, mainly CONSORT [12] and STROBE [13].
3.4. Delphi Round IV: The Second Consensus Confer-
ence. Another conference was held in order to discuss
the reassessed ﬁrst checklist looking at the purposes of
exploratory and conﬁrmatory experiments. The ﬁnal list,
unanimously agreed upon, is presented in Table 1:“ I t e m st o
be included when Reporting Experiments in Homeopathic
Basic Research”. It was then decided to refrain from estab-
lishing an evaluation score. As an additional step, the group
selected those items from the ﬁrst list that were considered to
be the minimum essential information needed for reviewing
publications in this ﬁeld. This new catalogue includes all
parts readers should know to clearly follow the experiments
and to fully understand the results. The catalogue will be
published after an internal reviewing process and test of
practicability.
3.5. Delphi Round V: Rewording of the Checklist Supplemented
with Explanations. In the last round detailed explanations
for each item based on the ﬁrst catalogue were written,
reassessed by all participants and supplemented with exam-
ples (available from the corresponding author). Often it is
not possible to give all information due to space limitations
of the journal. Therefore we recommend authors to refer to
a website address to make further information available. If
certain methods or the procedure of positive and negative
controls are already published, it may be suﬃcient to refer
to that publication. As publications often report on several
experimentsperformedwithregardtooneresearchquestion,
thereportshoulddistinguishbetweenthesingleexperiments
and make them obvious to the reader. Furthermore, it is
important to make clear if the experiment was designed for
explorative or conﬁrmatory purpose and whether it followed
a speciﬁc hypothesis or not.
4. Discussion
Accurate reporting is a prerequisite for critical interpretation
of any research study and its ﬁndings. Without accurate
reporting it is not possible to assess the merits of a study.
Any positive ﬁndings of basic research experiments on
high dilutions or potencies are likely to stir controversy
in the academic community. If details in the publication
(or an additional accessible report) are insuﬃcient to allow
repetition of experiments performed or to assess potential
threats to validity, the value of a potentially important
experimentisstronglycompromised.Inan18-monthDelphi
process we have tried to come up with a checklist aimed at
helping authors to prepare high quality manuscripts on their
homeopathicbasicresearchexperiments,andathelpingpeer
reviewers, editors and readers to check whether reporting
accurately reﬂects their experiments.
Shortcomings in reporting experiments are not at all
unique to homeopathy but a general phenomenon. The
limited space in journals, speciﬁc style and editorial pressure
often force authors to shorten their paper to an extent where
a detailed description becomes impossible. However, even
with limited space, a good manuscript can provide a lot
of relevant details, and the internet makes it possible to
make more detailed reports easily available to interested
researchers. In clinical and epidemiological research several
checklists to improve reporting quality have been developed
within the last number of years. The ﬁrst attempt to improve
quality of reporting randomized clinical trials was the
CONSORT statement in 1996 [14]. This document has been
revised in 2001 [12] and 2005 [15], and recently further doc-
uments have become available for improving the reporting
of abstracts [16], pragmatic trials [17], non-pharmacological
trials [18] (see also http://www.consort-statement.org/). The
necessity of CONSORT was recently encouraged by the
poor standards common in reporting RCTS in Tai Chi
interventions [19] as well as the poor standard of reporting
in Chinese journals [20].
QUORUM provides a guideline for reporting meta-
analyses [21, 22]. An evolution of this guideline was devel-
oped by an international group: Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA) [23].
For observational studies, including cohort, case-control
and cross-sectional studies STROBE emerged [13], recently
extended with STREGA (STRengthening the Reporting of
Genetic Association studies) [24]. Comparable lists are
available for trials in acupuncture: STRICTA [25]i sa l r e a d y
discussed [26] and assessed [27]. For complete and accurate
reporting of studies of diagnostic accuracy (STARD) an item
list was compiled [28]. Standards for Quality Improvement
Reporting Excellence (SQUIRE) were published to enhance
reporting on quality improvement studies in health care
[29]. RedHot [30], an unoﬃcial extension for CONSORT,
was established to assist reporting on homeopathic treat-
ments in clinical trials. A further CONSORT statement was
compiled [31] concerning randomized, controlled trials of
herbal interventions, evaluated in a systematic review of
instruments developed to critically assess the quality of trials
on the eﬃcacy of natural health products [32]. A complete
collection of available reporting guidelines can be found at
EQUATOR (Enhancing the QUAlity and Transparency Of
health Research), a new international initiative based on a
network concept [33].
Basic research is diﬀerent from clinical and epidemi-
ological research, and reporting guidelines comparable to
those described above for clinical research do not exist in
this area outside of homeopathy. In biological sciences there
are some groups working on standards of data presentation.
These initiatives were derived from research groups dealing
with microarray experiments and provide several checklists
on how to report and deal with large numbers of data
[34]. An overview of these activities can be found at the
homepage of MIBBI (Minimum Information for Biological4 Evidence-Based Complementary and Alternative Medicine
Delphi I
Preparatory work
Delphi II
(Verhagen et al.):
Absolutely necessary (4 points),
Moderately necessary (3 points),
N e u t r a l( 2p o i n t s ) ,
Moderately unnecessary or disagree (1 points),
Discussion on results of Delphi I, the objectives of the
catalogue and its form, necessity of an evaluation score
Delphi IV
Final discussion on catalogue of items for reports,
on how to handle an evaluation score and selection of
items necessary for reviews
Delphi III
catalogue according to existing catalogues in clinical
research
Delphi V
Final catalogues were sent out to all participants to
-Revise suggested explanation
-Add examples for a good publication
Evaluation of the questionnaire
58 items evaluated by the 5-point-likert-scale
Strongly unnecessary or disagree (0 points)
Development of a questionnaire
Review of all existing scales in basic research plus
criteria used in the two existing evaluation scores
Consensus conference 17th October 2007
Consensus conference 11th December 2007
Reduction and phrasing of items
Headings, subheadings and structure of the
Phrasing of items, explanation, examples
-Give their consent to publication of the results
Figure 1: Flow chart of the Delphi process realized from October 2007 to March 2009 among a group of European research on homeopathy
for developing the checklist REHBaR.
and Biomedical Investigations) http://www.mibbi.org or the
MGED (Microarray Gene Expression Data)s o c i e t y .
Our checklist is compiled for experiments on homeopa-
thy and how to report each step of experiment which is
important to understand and appreciate the results.
A ﬁrst proposal for a reporting guideline in homeopathy
was introduced in 1991 [35]. It focused on experiments
dealing with ultra low dose eﬀects (serial dilutions and
potencies).
The group refrained from establishing a score for assess-
ing quality, as had been common in the past, in clinical
research [36]. In the current state it was thought that it is
not feasible to propose clear-cut criteria for assessing what
constitutes good and bad basic research beyond generally
accepted standards. Furthermore, a lot of basic research
experiments are explorative and often procedures cannot
follow a predictable outline. Research questions tend to be
more complex than the methodologically straightforward
question of eﬃcacy. Unexpected eﬀects are common, either
due to the potentization process, the level of potentization
or the substance itself. In exploratory experiments it is
often not obvious to which part of the intervention the
eﬀect refers to and to what extent. A precise description
of the manufacturing and the Pharmacopoeias of the test
and control substances are therefore indispensable. If the
expected eﬀect is caused by the succussion process only,
unpotentized solvent is the adequate control. If the eﬀect is
expectedtobecausedbyapotentizedsubstance,apotentized
solventoranotherpotentizedsubstance(atthesamepotency
level) is adequate. When investigation was performed on the
Similia Principle, a variety of substances, which represent
diﬀerent degrees of similarity with the diseased state, can
be chosen as control. It is important to explain why which
control was selected relating to the underlying questions
of research, for example, the Similia Principle or Isopathy.
In this context the role of individualization in experiments
performed about the Similia Principle or the deﬁnition of
Isopathy should be taken into account.
Whether quality assessment scores make sense in the
future remains to be discussed. In clinical research there
is a clear trend to assess single components of quality
and investigate their impact on outcomes instead of using
questionable summary scores. “One commonly-used scale
was developed by Jadad and colleagues for randomized trials
in pain research [37]. The use of this scale is explicitly
discouraged. As well as suﬀering from the generic problems
of scales, it has a strong emphasis on reporting rather than
conduct, and does not cover one of the most important
potential biases in randomized trials, namely allocation
concealment.” (Cochrane Handbook, Chapter 8.3.3) [10].Evidence-Based Complementary and Alternative Medicine 5
Table 1: Items to be included when reporting experiments in REHBaR.
Item No. Descriptor
Title 1 Title indicates the experimental model and intervention
Abstract 2 Abstract provides an informative and balanced summary of what was done and found
Introduction
Background 3
Scientiﬁc background, presentation of experimental model(s). explanation of rationale, including
homeopathic principles (e.g., similia principle, potentization, proving) and type of homeopathy
(isopathy, classical versus complex homeopathy)
Objectives/Hypotheses 4
Objectives and hypotheses with outcome measures. For conﬁrmatory experiments: speciﬁc
hypotheses and clearly deﬁned primary outcome measure. For exploratory experiments:
hypotheses inducing the investigations
Materials and methods
Materials 5 Detailed description of all used materials (e.g., biological system, devices, substances,
instruments)
Materials (homeopathy speciﬁc) 6 Manufacturer, pharmacopoeia (or process) of medications, potency and steps of dilution,
dilution method, substance starting point of dilution (e.g., mother tincture. D1, nosode)
Homeopathic controls 7 Precise details on the preparation of the control substance
System performance controls 8 Report on negative and positive controls
Quality control 9 Procedures and eﬀorts used to enhance the quality and reliability of the experimental procedure
Object of investigation 10 Selection criteria for the particular system used: in vivo, in vitro, biological, physical, biochemical
Experimental setup 11 Detailed description of experimental conditions and procedure
Replication 21 If experiment has internal replications, detailed description is given of which materials were
reused and which have been changed
Parameters 13 All measured parameters described in detail
Intervention 14 Precise details of the interventions intended for each group and how and when they were actually
administered
Allocation 15 Method used to generate the group allocation including details (e.g., randomization, blocking,
stratiﬁcation)
Blinding 16 Description if any procedures or interventions were concealed (if yes, details given)
Statistical methods 17 Statistical tests and procedure of calculation are described: Methods for additional analyses like
adjusted analyses
Results
Numbers analysed 18 Number of experiments with exact number of treated units per setting which were included in
each analysis and reporting missing samples, drop outs
Data (descriptive) 19 Results are given in tables or ﬁgures showing mean or median together with variability (e.g., SD
and/or range) for absolute data (and diﬀerences)
Data (inferential) 20 Gives appropriate measures of eﬀect size uncertainty and probability
Discussion
Interpretation 21 Interpretation of the results, taking into account study hypotheses, sources of potential bias or
imprecision
Evidence 22 General interpretation of results in the context of current evidence. Discuss the
generalizability/external validity of the study results
Experimental model 23 Explanation why this model, these parameters were chosen and its adequacy for answering the
questions including homeopathic aspects
REHBaR was developed with a standard consensus
method among an international team of researchers with
experience in basic and clinical research in homeopathy,
experimental physiology, general research methodology and
statistics. All members commented on intermediate and the
ﬁnal version of the checklist. Obviously, the team was a
relatively small sample of individuals, and other researchers
might have introduced other items. The current list has to be
c o n s i d e r eda saﬁ r s ttrya n di ti sh o pedt h a ti tp r o v e su s e f u lt o
enhance the quality of reporting basic research experiments
in homeopathy. We encourage the use of the list, critical
feedback and hope to be able to provide an improved version
in a few years.
Acknowledgments
The authors are grateful to logistic support by the German
Karl and Veronica Carstens-Foundation oﬀering a platform
for communication and coordination of the Delphi process.6 Evidence-Based Complementary and Alternative Medicine
Furthermore, the foundation provided a grant for two
consensus conferences.
References
[ 1 ]S .B a u m g a r t n e r ,D .S h a h ,J .S c h a l l e r ,U .K ¨ ampfer, A. Thur-
neysen, and P. Heusser, “Reproducibility of dwarf pea shoot
growth stimulation by homeopathic potencies of gibberellic
acid,” Complementary Therapies in Medicine,v o l .1 6 ,n o .4 ,p p .
183–191, 2008.
[2] R. Van Wijk and H. Albrecht, “Classiﬁcation of systems and
methods used in biological basic research on homeopathy,”
Homeopathy, vol. 96, no. 4, pp. 247–251, 2007.
[3] C. M. Witt, M. Bluth, H. Albrecht, T. E. R. Weißhuhn, S.
Baumgartner, and S. N. Willich, “The in vitro evidence for an
eﬀect of high homeopathic potencies—a systematic review of
the literature,” Complementary Therapies in Medicine, vol. 15,
no. 2, pp. 128–138, 2007.
[4] J. Schulte, “About quality and standards in ultra high dilu-
tion research and research on homeopathy,” in Ultra High
Dilution—Physiology and Physics,P .C .S .J .E n d l e r ,E d . ,
pp. 171–176, Kluwer Academic Publishers, Dordrecht, The
Netherlands, 1994.
[5] W. Linde, D. Melchart, W. B. Jonas, and J. Hornung, “Ways to
enhance the quality and acceptance of clinical and laboratory
studies in homoeopathy,” British Homoeopathic Journal, vol.
83, no. 1, pp. 3–7, 1994.
[6] S. Baumgartner, P. Heusser, and A. Thurneysen, “Method-
ological standards and problems in preclinical homoeo-
pathic potency research,” Forschende Komplementarmedizin
und Klassische Naturheilkunde, vol. 5, no. 1, pp. 27–32, 1998.
[7] K. Linde, W. B. Jonas, D. Melchart, F. Worku, H. Wagner,
and F. Eitel, “Critical review and meta-analysis of serial
agitated dilutions in experimental toxicology,” Human and
Experimental Toxicology, vol. 13, no. 7, pp. 481–492, 1994.
[8] C. Becker-Witt, T. E. R. Weißhuhn, R. L¨ udtke, and S. N.
Willich, “Quality assessment of physical research in homeopa-
thy,” Journal of Alternative and Complementary Medicine, vol.
9, no. 1, pp. 113–132, 2003.
[9] H. Linstone and M. Turoﬀ, “The Delphi method:
techniques and applications,” 2002, http://www.is.njit.edu/
pubs/delphibook/.
[10] J. Higgins and D. Altman, “Cochrane handbook for systematic
reviews of interventions version 5.0.1.,” in The Cochrane
Collaboration, 2009, http://www.cochrane-handbook.org.
[11] P. J¨ uni, A. Witschi, R. Bloch, and M. Egger, “The hazards of
scoring the quality of clinical trials for meta-analysis,” Journal
oftheAmericanMedicalAssociation,vol.282,no.11,pp.1054–
1060, 1999.
[12] D. Moher, K. F. Schulz, and D. G. Altman, “The CONSORT
statement: revised recommendations for improving the qual-
ity of reports of parallel-group randomized trials,” Journal of
the American Podiatric Medical Association,v o l .9 1 ,n o .8 ,p p .
437–442, 2001.
[13] J. P. Vandenbroucke, E. Von Elm, D. G. Altman et al.,
“Strengthening the reporting of observational studies in epi-
demiology (STROBE): explanation and elaboration,” Annals
of Internal Medicine, vol. 147, no. 8, pp. W163–W194, 2007.
[14] C. Begg, M. Cho, S. Eastwood et al., “Improving the quality
of reporting of randomized controlled trials: the CONSORT
statement,” Journal of the American Medical Association, vol.
276, no. 8, pp. 637–639, 1996.
[15] D. Moher,K.F.Schulz, andD.Altman,“TheCONSORT state-
ment: revised recommendations for improving the quality of
reportsofparallel-grouprandomizedtrials2001,”Explore,vol.
1, no. 1, pp. 40–45, 2005.
[16] S. Hopewell, M. Clarke, D. Moher et al., “CONSORT for
reporting randomized controlled trials in journal and confer-
ence abstracts: explanation and elaboration.,” PLoS Medicine,
vol. 5, no. 1, article no. e20, 2008.
[17] M. Zwarenstein, S. Treweek, J. J. Gagnier et al., “Improving the
reporting of pragmatic trials: an extension of the CONSORT
statement.,” BMJ, vol. 337, article no. a2390, 2008.
[18] I. Boutron, F. Tubach, B. Giraudeau, and P. Ravaud, “Method-
ological diﬀerences in clinical trials evaluating nonpharma-
cological and pharmacological treatments of hip and knee
osteoarthritis,” Journal of the American Medical Association,
vol. 290, pp. 1062–1070, 2003.
[19] J. Y. Li, Y. F. Zhang, G. S. Smith, C. J. Xue, Y. N. Luo, and W.
H. Chen, “Quality of reporting of randomized clinical trials
inTaiChiinterventions—asystematicreview,”Evidence-Based
Complementary and Alternative Medicine. In press.
[20] L.Xu,J.Li,M.Zhang,C.Ai,andL.Wang,“Chineseauthorsdo
need CONSORT: reporting quality assessment for ﬁve leading
Chinese medical journals,” Contemporary Clinical Trials, vol.
29, no. 5, pp. 727–731, 2008.
[21] D. Moher, D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.
F. Stroup, “Improving the quality of reports of meta-analyses
of randomised controlled trials: the QUOROM statement.
Quality of reporting of meta-analyses,” Lancet, vol. 354, pp.
1896–900, 1999.
[22] D. L. Turpin, “CONSORT and QUOROM guidelines for
reporting randomized clinical trials and systematic reviews,”
American Journal of Orthodontics and Dentofacial Orthopedics,
vol. 128, pp. 681–685, 2005.
[23] D. Moher, A. Liberati, J. Tetzlaﬀ, and D. G. Altman, “Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement,” Journal of Clinical Epidemiology, vol. 62,
pp. 1006–1012, 2009.
[24] J. Little, J. P. T. Higgins, J. P. A. Ioannidis et al., “Strengthening
the reporting of genetic association studies (STREGA)-an
extension of the strengthening the reporting of observational
studies in epidemiology (STROBE) statement,” Journal of
Clinical Epidemiology, vol. 62, no. 6, pp. 597–608, 2009.
[25] H. MacPherson, A. White, M. Cummings, K. Jobst, K. Rose,
and R. Niemtzow, “Standards for reporting interventions in
controlled trials of acupuncture: the STRICTA recommenda-
tions,” Complementary Therapies in Medicine,v o l .9 ,n o .4 ,p p .
246–249, 2001.
[26] S. L. Prady and H. MacPherson, “Assessing the utility of the
standards for reporting trials of acupuncture (STRICTA): a
survey of authors,” Journal of Alternative and Complementary
Medicine, vol. 13, pp. 939–943, 2007.
[27] S. L. Prady, S. J. Richmond, V. M. Morton, and H. MacPher-
son, “A systematic evaluation of the impact of STRICTA
and CONSORT recommendations on quality of reporting for
acupuncture trials,” PLoS ONE, vol. 3, no. 2, article no. e1577,
2008.
[28] P. M. Bossuyt, J. B. Reitsma, D. E. Bruns et al., “Towards
complete and accurate reporting of studies of diagnostic
accuracy: the STARD initiative,” Radiology, vol. 226, no. 1, pp.
24–28, 2003.
[29] F. Davidoﬀ, P. Batalden, D. Stevens, G. Ogrinc, and S. E.
Mooney, “Publication guidelines for quality improvement
studies in health care: evolution of the SQUIRE project.,”
British Medical Journal, vol. 338, article no. a3152, 2009.Evidence-Based Complementary and Alternative Medicine 7
[ 3 0 ]M .E .D e a n ,M .K .C o u l t e r ,P .F i s h e r ,K .A .J o b s t ,a n d
H. Walach, “Reporting data on homeopathic treatments
(RedHot): a supplement to CONSORT,” Journal of Alternative
and Complementary Medicine, vol. 13, no. 1, pp. 19–23, 2007.
[31] J. J. Gagnier, H. Boon, P. Rochon, D. Moher, J. Barnes, and
C. Bombardier, “Reporting randomized, controlled trials of
herbal interventions: an elaborated CONSORT statement,”
Annals of Internal Medicine, vol. 144, no. 5, pp. 364–367, 2006.
[32] A. M. Whelan, T. M. Jurgens, and L. Lord, “Evaluating the
quality of randomized controlled trials that examine the eﬃ-
cacy of natural health products: a systematic review of critical
appraisal instruments,” Evidence-Based Complementary and
Alternative Medicine. In press.
[33] I. Simera, D. Moher, J. Hoey, K. F. Schulz, and D. G. Altman,
“The EQUATOR Network and reporting guidelines: helping
toachievehighstandardsinreportinghealthresearchstudies,”
Maturitas, vol. 63, no. 1, pp. 4–6, 2009.
[34] C.F.Taylor,D.Field,S.-A.Sansoneetal.,“Promotingcoherent
minimum reporting guidelines for biological and biomedical
investigations: the MIBBI project,” Nature Biotechnology, vol.
26, no. 8, pp. 889–896, 2008.
[35] J.HornungandK.Linde,“Guidelinesfortheexactdescription
of the preparation and mode of application of serial dilutions
and potencies in publications on ultra low dose eﬀects and
homeopathic research—a proposal,” Berlin Journal of Research
in Homeopathy, vol. 1, pp. 121–123, 1991.
[36] D. Moher, A. R. Jadad, G. Nichol, M. Penman, P. Tugwell,
and S. Walsh, “Assessing the quality of randomized controlled
trials: an annotated bibliography of scales and checklists,”
Controlled Clinical Trials, vol. 16, no. 1, pp. 62–73, 1995.
[37] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the
quality of reports of randomized clinical trials: is blinding
necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12,
1996.